Immune Health
Thymosin alpha-1, the LL-37 antimicrobial peptide, immune modulation and the long COVID question.
Are peptides a treatment for long COVID?
An honest, evidence-first answer: no peptide is an approved or proven treatment for long COVID as of 2026. Here is what the small, mostly acute-COVID and animal research on BPC-157, thymosin alpha-1, and larazotide actually shows, and what a licensed clinician can do instead.
LL-37 peptide: what your gut already makes, and what the trials actually found
A primary-sourced look at the LL-37 peptide (human cathelicidin) from the gut and immune side: what it does in the intestinal lining, what the human wound-healing trials, including Promore Pharma's HEAL LL-37, actually reported, the side effects seen so far, and why the online claims run ahead of the evidence.
What does thymosin alpha-1 do? Benefits, evidence and how it compares
What thymosin alpha-1 (thymalfasin, Zadaxin) does to the immune system, which of its claimed benefits have human evidence (hepatitis, sepsis, vaccine response, COVID-19) and which do not, its known side effects, how long trials gave it, and how it compares with LL-37, KPV and BPC-157 as an "immune peptide", with every claim cited to a primary or peer-reviewed source.